Affiris plans clinical trials of Parkinson's disease vaccine
This article was originally published in Scrip
Executive Summary
Preclinical tests of Affiris’s PD01 vaccine against Parkinson’s disease have confirmed its mechanism of action. The Vienna-based company is now planning clinical trials, which may begin next year.